



*Haemophilia* (2013), 19 (Suppl. 2), 1–4

## PROGRAMME

### WEDNESDAY, 6 FEBRUARY

12.00-19.00      **REGISTRATION**

#### Satellite symposium *INSPIRATION*

All haemophilias are equal. But some haemophilias are more equal than others. *With apologies to George Orwell and Animal Farm!*

14.30-14.35      **Chairman's introduction**  
*C. Ludlam, UK*

14.35-15.15      **Acquired haemophilia**  
How do we recognise and how do we manage this rare condition? *P. Collins, UK*

15.15-15.55      **Prophylactic use of haemophilia B: pros and cons**  
*L. Valentino, USA – pros*  
*C. Hermans, BE – cons*

15.55-16.00      **Closing remarks and conclusions**  
*C. Ludlam, UK*

16.00-16.30      **Break**

#### Satellite symposium *SOBI / BIOGEN IDEC HEMOPHILIA*

Emerging Therapies in Development: Implications for Haemophilia Care

*Chair: C. Negrier, FR*

*Co-Chair: B. Volck, SE*

16.30-16.40      **Introduction: Potential impact of emerging products in development and regimens for the management of haemophilia**  
*C. Negrier, FR*

16.40-16.55      **Fc Fusion technology: Evaluating a natural pathway to potentially prolong the half-life of therapeutic proteins**  
*P. Lind, SE*

16.55-17.05      **From potency assignment to clinical assays – Monitoring the activity of potential new clotting factors in development**  
*J. Sommer, USA*

17.05-17.25      **Ongoing clinical development of rFVIII<sup>h</sup> & rFIX<sup>h</sup>**  
*D. Perry, UK*

17.25-17.45      **Considering a tailored approach to haemophilia care**  
*C. Hermans, BE*

17.45-18.00      **Discussion**

18.00-18.15      **Break**

#### Satellite symposium *OCTAPHARMA*

*followed by a 19.45-22.00 Buffet dinner at the hotel*

In the battle against FVIII inhibitors: Is there a place for personalized ITI?

18.15-18.20      **Welcome and Introduction**  
*J. Oldenburg, W. Kreuz, DE*

## 2 PROGRAMME

- 18.20-19.00      **ObsITI – new interim data on VWF-containing FVIII from a prospective ongoing global observational study in ITI**  
*W. Kreuz, C. Escuriola-Ettingshausen, DE*
- 19.00-19.20      **Can the host genetic factors such as F8 or polymorphism of immune response genes act as predictors of ITI outcome?**  
*J. Oldenburg, A. Pavlova, DE*
- 19.20-19.40      **TGA as a tool to monitor FVIII efficacy and to predict the risk of bleeding during ITI therapy**  
*C. Negrier, Y. Dargoud, FR*
- 19.40-19.45      **Concluding remarks**  
*J. Oldenburg, DE*
- 20.00              **EAHAD Executive Committee Meeting**  
Hotel Sofitel Warsaw Victoria, room Ujazdów

## THURSDAY, 7 FEBRUARY

### Satellite symposium *BAXTER*

08.00-09.30

Towards a personalized prophylaxis in haemophilia A patients

1. Beyond the concept: FVIII PK assessment tools *S. Bjorkman*
2. Tailoring the dose for a bleed-free life *P. Collins*
3. Personal experience and need for registries to capture data from emerging personalized care *J. Oldenburg*

09.30-10.00      **Break**

10.00-10.10      **Opening the congress**

*J. Windyga, PL*

10.10-11.50      **SCIENTIFIC SESSION 1**

**Update on working parties and international studies**

*Chairs: J. Astermark, SE*

*P. de Moerloose, CH*

11.50-12.00      **Update on WFH Twinning Programme**

*C. Hudon, NL, J. Windyga, PL*

12.00-12.30      **Break**

### Satellite symposium *PFIZER*

Outcomes Assessment in Haemophilia: Science, Practice, Standardisation

12.30-12.40      **Welcome and Introduction**

*Co-Chairmen: J. Astermark, SE, J. Windyga, PL*

12.40-13.00      **Early detection, future success: the role of ultrasound in joint management**

*C. Martinoli, IT*

13.00-13.20      **Assessing outcomes in practice: now and in the future**

*J. Oldenburg, DE*

13.20-13.40      **Standardising outcomes assessment: a managed approach**

*J. Astermark, SE*

- 13.40-14.00 **Panel Discussion**  
*Moderated by Co-Chairmen*
- 14.00-14.30 **Break**
- 14.30-16.00 **SCIENTIFIC SESSION 2**  
**Controversies in prophylaxis**  
*Chairs: K. Fischer, NL, K. Zawilska, PL*
1. **Prophylaxis in countries with limited resources**  
*A. Batorova, SK*
  2. **Prophylaxis in VWD patients**  
*E. Berntorp, SE*
  3. **Prophylaxis in adult haemophiliacs**  
*P. Collins, UK*
- 16.00-16.30 **Break**
- 16.30-17.30 **SCIENTIFIC SESSION 3**  
**Treatment related issues part I**  
*Chairs: C. Hermans, BE, A. Klukowska, PL*
- Inhibitors in mild and moderate hemophilia**  
*R.D'Oiron, FR*
- Advantages and drawbacks of continuous infusion in haemophilia and allied disorders**  
*P.A. Holme, NO*
- 17.30-18.30 **EAHAD General Assembly**  
**Free time**

**FRIDAY, 8 FEBRUARY**

- 8.30-10.00 **SCIENTIFIC SESSION 4**  
**Do we know haemophilia B?**  
*Chairs: E. Santagostino, IT, L. Nemes, HU*
1. **Is haemophilia B less severe than haemophilia A?**  
*P.M. Mannucci, IT*
  2. **Arosenius Lecture 2013**  
**Pharmacokinetics of pdFIX and rFIX concentrates – implications for prophylaxis and on demand therapy**  
*S. Bjorkman, SE*
  3. **Long-term prophylaxis in hemophilia B**  
*R. Ljung, SE*
- 10.00-10.30 **Break**
- 10.30-12.00 **SCIENTIFIC SESSION 5**  
**Treatment related issues part II**  
*Chairs: J. Windyga, PL, J. Oldenburg, DE*

#### 4 PROGRAMME

**1. Current issues on transmission of infective agents by concentrates**

*R. Lassila, FI*

**2. Is thrombosis a real threat in patients with rare inherited bleeding disorders?**

*A. Coppola, IT*

**3. Management of bleeding complications in patients receiving new oral anti-IIa and anti-Xa anticoagulants**

*C. Kessler, USA*

12.00-14.00

**LUNCH SESSION - POSTER VIEWING AND MANNING**

*Coordinators: A. Rocino, IT, C. Hermans, BE, P. de Moerloose, CH*

14.00-15.00

**SCIENTIFIC SESSION 6**

Late breaking news

*Chairs: M. Makris, UK, J. Astermark, SE*

15.00-15.15

**Congress conclusion**

*Jan Astermark, SE*